LVM Capital Management Ltd. MI Trims Position in Stryker Corporation (SYK)

LVM Capital Management Ltd. MI lessened its stake in Stryker Corporation (NYSE:SYK) by 11.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 26,348 shares of the medical technology company’s stock after selling 3,542 shares during the period. LVM Capital Management Ltd. MI’s holdings in Stryker were worth $4,080,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Jaffetilchin Investment Partners LLC lifted its stake in shares of Stryker by 41.5% in the fourth quarter. Jaffetilchin Investment Partners LLC now owns 2,215 shares of the medical technology company’s stock valued at $343,000 after buying an additional 650 shares during the period. Sit Investment Associates Inc. lifted its stake in shares of Stryker by 114.3% in the fourth quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock valued at $128,000 after buying an additional 440 shares during the period. Founders Capital Management LLC lifted its stake in shares of Stryker by 1.4% in the fourth quarter. Founders Capital Management LLC now owns 25,790 shares of the medical technology company’s stock valued at $3,993,000 after buying an additional 350 shares during the period. DnB Asset Management AS lifted its stake in shares of Stryker by 2.8% in the fourth quarter. DnB Asset Management AS now owns 36,495 shares of the medical technology company’s stock valued at $5,651,000 after buying an additional 1,000 shares during the period. Finally, Oak Point Wealth Management bought a new stake in shares of Stryker in the fourth quarter valued at about $145,000. Institutional investors and hedge funds own 74.90% of the company’s stock.

A number of brokerages have commented on SYK. Robert W. Baird upgraded shares of Stryker from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $161.00 to $173.00 in a research note on Thursday, November 16th. SunTrust Banks restated a “buy” rating and set a $161.00 price target on shares of Stryker in a research note on Friday, November 17th. Wells Fargo & Co raised their price target on shares of Stryker from $160.00 to $166.00 in a research note on Friday, October 27th. Barclays raised their price target on shares of Stryker from $137.00 to $148.00 and gave the stock an “underweight” rating in a research note on Friday, October 27th. Finally, Zacks Investment Research upgraded shares of Stryker from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $156.60.

Shares of Stryker Corporation (NYSE:SYK) opened at $159.54 on Thursday. The firm has a market cap of $59,710.00, a P/E ratio of 34.02, a PEG ratio of 2.30 and a beta of 0.78. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.61 and a current ratio of 2.37. Stryker Corporation has a fifty-two week low of $119.17 and a fifty-two week high of $164.20.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.02. The company had revenue of $3.01 billion during the quarter, compared to analyst estimates of $2.97 billion. Stryker had a net margin of 14.67% and a return on equity of 24.11%. The company’s revenue was up 6.1% on a year-over-year basis. During the same quarter last year, the business posted $1.39 earnings per share. equities research analysts forecast that Stryker Corporation will post 6.47 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 31st. Stockholders of record on Friday, December 29th will be issued a dividend of $0.47 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.43. The ex-dividend date is Thursday, December 28th. This represents a $1.88 annualized dividend and a dividend yield of 1.18%. Stryker’s dividend payout ratio (DPR) is presently 40.09%.

In other news, insider Lonny J. Carpenter sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $155.34, for a total transaction of $776,700.00. Following the completion of the sale, the insider now owns 83,207 shares of the company’s stock, valued at $12,925,375.38. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 7.40% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.themarketsdaily.com/2018/01/11/lvm-capital-management-ltd-mi-trims-position-in-stryker-corporation-syk.html.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply